Home » Market News » DirectorsTalk Highlights » Open Orphan pushes ahead with hVIVO COVID Clear, the ‘most accurate’ antibody test
Open Orphan PLC

Open Orphan pushes ahead with hVIVO COVID Clear, the ‘most accurate’ antibody test

Open Orphan updates investors on the progress it’s making in its target of testing 3,000 people a day, pushing to 6,000, to confirm Covid-19 antibodies. It’s test is for corporations only.

Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data). 

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.